Here's What Makes the Trend Reversal More Likely for EVAX Shares of Evaxion Biotech A/S Sponsored ADR (EVAX) have been struggling lately and have lost 11.1% over the past four weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road. The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsidin ...

On May 7, 2024, the Company received a Nasdaq equity deficiency letter. This deficiency is partly a consequence of the IFRS accounting treatment of the Company's investor warrants requiring treating these as a derivative liability, hence reducing shareholder's equity. The derivative liability treatment is the result of the Company's investor warrant's exercise price being in USD while the Company's share capital is in DKK. As communicated on May 24, the Company has subsequently agreed with the investor warr ...

COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2024 financial results. Business Highlights Since Last Quarterly Update Since the 2023 full year financial results were released, the Company has continued to make progress on its three-pronged business model focusing on Targets, Pipeline, and Res ...

COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on May 7, 2024, it received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Department notifying the Company that it is not currently in compliance with the minimum stockholders' equity requirement. Nasdaq Listing Rule 5550(b)(1) require ...

Evaxion Biotech A/S (EVAX) , along with its undisclosed partner, announced the successful completion of a series of large non-rodent animal infection studies, testing antigens from its investigational EVX-B1 vaccine candidate, which is being developed to treat Staphylococcus aureus (S. aureus) infection.Per the companies, in the completed pre-clinical studies, treatment with EVX-B1 antigens significantly reduced the disease burden. Based on such positive results, Evaxion and its partner are currently discus ...

Financial Data and Key Metrics Changes - The net loss for 2023 amounted to $22.1 million, compared to a net loss of $23.2 million in the previous year, indicating a slight improvement in financial performance [47] - Research and development expenses for 2023 totaled $11.9 million, while administrative expenses were $20.4 million, reflecting a focus on optimizing cash burn without compromising long-term growth [46][61] - Cash and cash equivalents as of December 31, 2023, were $5.6 million, with expectations that existing funds will be sufficient to cover operations into February 2025 following a public offering [67] Business Line Data and Key Metrics Changes - The company reported strong progress in its R&D pipeline, particularly with the EVX-01 personalized cancer vaccine, which is set to provide one-year clinical readout in Q3 2024 [41][54] - The EVX-B1 project against Staphylococcus aureus showed promising results in large animal models, marking a significant milestone in vaccine development [42][44] - The precision vaccine project is on track, with encouraging initial Phase 2 data from EVX-01 and ongoing discussions for further development [68] Market Data and Key Metrics Changes - The company is experiencing interest in both its infectious disease and oncology pipelines, indicating a balanced market demand for its products [83] - The collaboration with MSD Global Health Innovation Fund has positioned the company favorably in the market, with MSD being the largest shareholder [51] Company Strategy and Development Direction - The company has refined its strategy to focus on a three-pronged business model based on its AI immunology platform, which includes targets, pipeline, and responder models [34][35] - A multi-partner approach is emphasized for value realization, with ongoing discussions for partnerships to fund operational cash burn [52][53] - The company aims to progress its precision vaccine project and capitalize on the unmet needs in both cancer and infectious disease markets [60][68] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress made in the past six months, highlighting strong execution of the refined strategy and successful collaborations [49] - The focus remains on advancing various partnership discussions to support operational funding and growth [52][60] - Management anticipates significant milestones in 2024, including the conclusion of key collaborations and clinical trials [68] Other Important Information - The company has reduced its organization by 30% during 2023 to optimize cash burn and align with its focused strategy [60] - The upcoming AI model version 5.0 is expected to enhance predictive capabilities, further supporting vaccine discovery efforts [80][81] Q&A Session All Questions and Answers Question: Can you provide more details on the collaboration and data for EVX-B1? - The company is currently in discussions with the collaborator, and the data is supportive of the compound, indicating a promising outlook for clinical efficacy [70][72] Question: What are the next steps for EVX-B3 with MSD? - The next steps involve final IND-enabling activities, which are expected to take 1 to 1.5 years before clinical trials can be initiated [79] Question: What is unique about the new AI model version? - The new version incorporates additional building blocks to enhance predictive capabilities and expand the training dataset, increasing the model's precision [80][81] Question: Is there a greater interest in infectious disease candidates compared to cancer? - The company has seen balanced interest in both infectious disease and oncology candidates, with no significant tilt towards one over the other [83] Question: What is the status of outstanding prefunded warrants? - Approximately $4 million remains outstanding related to prefunded warrants, which will be released as they are exercised [89] Question: Does the company have a policy for takeover bids? - The company cannot comment on potential takeover bids but will communicate any relevant information if necessary [101]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REP ...

The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologiesAI-Immunology™ outcompetes standard vaccine target discovery approaches and holds the promise of addressing serious unmet needsWith a unique modular architecture, AI-Immunology™ is scalable and adaptable towards partner needsThe potential of AI-Immunology™ is validated by established partnerships, including an ongoing vaccine collaboration ...

COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announces that it will host a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform on March 19, 2024, at 14:00 - 18:00 CET / 8:00 a.m. - 12:00 a.m. EST. The R&D Day will feature a series of talks from Evaxion's scientists and bioinformaticians, providing insights into ...

COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on February 05, 2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). Th ...